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Abstract: 
Regular haematological monitoring during clozapine treatment reduces the risk of 
complications and death from clozapine-related blood dyscrasias. However, many patients in 
the course of clozapine treatment develop neutropenia unrelated to drug treatment but 
which leads to treatment discontinuation.  The minimum haematological threshold allowed 
for continuation of clozapine treatment was recently lowered in the US, but not in the UK. In 
this case series, we present four cases where lowering the haematological cut-off to that used 
in the US, allowed treatment continuation.  Lowering the current UK threshold for clozapine 
cessation could avoid unnecessary interruptions in treatment with minimal impact on safety. 
 
Introduction: 
Haematological monitoring during clozapine treatment is mandated to reduce the risk of 
clozapine-induced neutropenia and agranulocytosis. The cut-off point for clozapine cessation 
is somewhat arbitrary in that the evidence base that underpins the threshold is weak and 
there are worldwide variations in haematological monitoring parameters. Chance findings of 
apparent neutropenia during clozapine treatment that is probably unrelated to drug 
 treatment occurs frequently, usually  leading to clozapine discontinuation. This in turn can 
lead to increased morbidity and prolonged hospitalisations and be detrimental to the quality 
of life of patients and their families.  A single false result may also preclude use of clozapine 
for life.  Given the increasing evidence that clozapine treatment is associated with reduced 
overall mortality (Wimberley et al 2017, Cho et al 2018), discontinuing clozapine in a patient 
with a marginal neutrophil count may not be in their long term interests.  
 
Ethnicity is a major determinant of an individual’s haematological profile, with neutrophil 
counts being substantially lower in people of African descent (Hsieh et al., 2007). Frequent, 
repeated and often unnecessary requests for blood tests accounts at least in part for the 
underutilisation of clozapine in these patients (Whiskey et al., 2011). The use of separate 
haematological reference values for black and white patients had been long argued and so 
the introduction of monitoring according to Benign Ethnic Neutropenia (BEN) guidelines in 
the United Kingdom was a welcome development.  This opened the way for patients that had 
hitherto been ineligible for this uniquely effective treatment.   
 
The United States Food and Drugs Administration (FDA) introduced new clozapine monitoring 
guidelines in 2015.  These guidelines give a lower Absolute Neutrophil Counts (ANC) cut-off 
for clozapine discontinuation (in both the general population and patients diagnosed with 
BEN) than in Europe.  In addition, the requirement for monitoring total white blood cells 
(WBC) and platelets has been removed.  It is expected that these changes will lead to many 
more patients in the United States being initiated and maintained on clozapine (Bastiampillai 
et al., 2016). 
 
 The question that arises is – are the new US guidelines as safe as non-US guidelines, and if 
they are, why have they not been adopted around the world?   
 
 
 
 
 
 
 Current UK  Guidelines Current US Guidelines 
Status General population 
criteria 
BEN criteria General population 
criteria 
BEN criteria 
Green* 
WBC 
Neutrophils 
 
 
≥ 3.5x109/l 
≥ 2.0x109/l 
 
≥ 3.0x109/l 
≥ 1.5x109/l 
 
Not mandatory 
≥ 1.5x109/l 
 
Not mandatory 
≥ 1.0x109/l 
Amber* 
WBC 
Neutrophils 
 
 
≥ 3.0 and < 3.5x109/l 
≥ 1.5 and < 2.0x109/l 
 
≥2.5 and < 3.0x109/l 
≥ 1.0 and < 1.5x109/l 
 
Not mandatory 
≥ 1.0 and < 1.5x109/l 
 
Not mandatory 
≥ 0.5 and < 1.0x109/l 
Red*  
WBC 
Neutrophils 
 
 
< 3.0x109/l 
< 1.5x109/l 
 
< 2.5x109/l 
< 1.0x109/l 
 
Not mandatory 
< 1.0x109/l 
 
Not mandatory 
< 0.5x109/l 
 
*Green – Continue treatment 
*Amber – increase monitoring frequency 
 *Red – Discontinue treatment 
 
 
In the following cases, adoption of the US Absolute Neutrophil Count (ANC) cut-off criteria 
enabled clozapine successful rechallenge.   
 
 
Case 1: 
Mr A is a 50-year old white British gentleman with a diagnosis of schizoaffective disorder. His 
first contact with psychiatric services was at around age 17 years. After various antipsychotic 
treatments, he started clozapine in 2000, which seemed to stabilise him very well over the 
years. In 2016 he was receiving clozapine 525 mg daily, amisulpride 200 mg BD and 
aripiprazole 5 mg daily. Over the 16-year period Mr A was on clozapine, he recorded several 
amber results that did not necessitate clozapine discontinuation. However in August 2016, he 
had a first red result with a neutrophil count of 1.25x109/l and a white cell count of 2.30x109/l 
which led to clozapine cessation. This period of neutropenia persisted over a two-week period 
where neutrophil counts ranged from 1.05 to 1.85x109/l and WBC from 1.90 to 3.00x109/l.  
There was no discernible medical explanation for the neutropenia. Upon discontinuation of 
clozapine, the patient suffered a significant deterioration in mental state requiring admission 
to a psychiatric intensive care unit. Treatment with high dose and combination antipsychotics 
did not alleviate his psychotic symptoms. Treatment with two courses of Electroconvulsive 
Therapy (ECT), each of 12 sessions, brought about a degree of improvement which was not 
sustained. Mr A remained thought-disordered and incoherent and was on a 2:1 nursing 
observation upon admission to our unit in November 2017. On admission, he was prescribed 
 olanzapine 30mg daily and lithium 800mg daily. His neutrophil count on admission was 
2.7x109/l and WBC 4.2x109/l. All other investigations were within normal limits apart from a 
slightly elevated fasting blood sugar.  
 
After haematology consultation, a care plan for clozapine rechallenge was developed and he 
was restarted. Within a few weeks, his mental state started to show significant improvement. 
However, within 3 months of restarting clozapine, he had recorded six amber results using 
the general population criteria, requiring multiple and frequent blood tests with neutrophil 
counts ranging from 1.6 to 1.9x109/l and WBC from 3.0 to 3.5x109/l. This prompted the team 
to refer for another haematology consultation and agreement was reached with the clozapine 
registry to use revised monitoring protocols in line with US criteria. At 6 months follow-up, 
there have been no further amber or red results on the new criteria and the patient continues 
to make progress on clozapine treatment without the need for frequent and repeated blood 
testing. 
 
Case 2:   
 
Mr B is a 49-year old white British male with a diagnosis of treatment-resistant schizoaffective 
disorder who was started on clozapine in 2003 and for the most part was treated with 
clozapine, sodium valproate and various antidepressants until 2015 when he stopped and 
refused to restart clozapine.  Although he had responded well to clozapine treatment and was 
living in the community during this period, he complained of a variety of side effects such as 
sedation and weight gain. After clozapine cessation, he was treated with numerous oral and 
long-acting antipsychotic drugs such as zuclopenthixol decanoate and olanzapine at 
 maximum licensed doses but without response.  Eventually, he was referred to our unit for a 
clozapine retrial. On admission to our unit in March 2017, his prescribed medications were 
zuclopenthixol decanoate 500mg weekly and sodium valproate 500mg daily. The blood 
picture showed WBC 3.6x109/l, neutrophils 1.8x109/l and platelets 131x109/l. All other blood 
results were normal.  In view of the plan to start clozapine, and our previously published 
evidence that sodium valproate treatment is associated with an increased risk of neutropenia 
in clozapine-treated patients (Meyer et al., 2015; Malik et al., 2018), sodium valproate was 
gradually discontinued.  However, the patient refused to accept lithium, which we use to 
provide mood stabilisation but which also has the capacity to boost neutrophil counts 
(Whiskey and Taylor, 2007).  Before clozapine initiation, the haematological picture had 
improved and WBC was 4.85x109/l, neutrophils 2.47x109/l and platelets 159x109/l. Clozapine 
was eventually commenced in May 2017 and the dose gradually increased. This was followed 
by significant improvement in mental state. Over the next 10 months, using general UK 
population criteria, there were four amber results and one red result. Consequently,  in March 
2018 we consulted with haematology specialists regarding lowering the monitoring 
parameters in accordance with the US protocol which was agreed and adopted by the 
clozapine registry. At 14 months follow up, the patient continued clozapine monotherapy 
without the need for discontinuation owing to low neutrophil counts using the modified 
criteria. 
 
 
 
Case 3 
 
 Ms C is a 46-year old white British female with a diagnosis of treatment-refractory 
schizophrenia. She was diagnosed with schizophrenia in 1996 at age 24. She was commenced 
on clozapine treatment in June 2000 to which she demonstrated a response, but after 3 
months on treatment, it was discontinued after two red results with a nadir of neutrophils at 
1.7x109/l and WBC of 2.85x109/l. Over the next 17 years, she was tried on a variety of first 
and second generation antipsychotic drugs without much improvement. Although clozapine 
was contemplated on a few occasions its use was not attempted until she was referred to our 
unit in 2017. On admission in November 2017, her prescribed medications were 
zuclopenthixol decanoate 500mg 2-weekly and the antidepressant agomelatine. Her 
psychotic symptoms were prominent and encompassed most aspects of her life. The main 
delusional themes revolved around passivity in religious, mythological and sexual ideas (first 
rank Schneiderian experiences), in addition to delusions of grandeur and persecution. There 
were also auditory, visual and somatic hallucinations, which had been effectively untreated 
for many years.  Her haematological profile on admission was normal with a WBC of 4.5x109/l, 
neutrophils of 3.5x109/l and a platelet count of 221x109/l. She had a slightly raised HBA1c of 
6.3% (on metformin).  All other biochemical tests were normal. We sought haematology 
advice and the patient was able to commence clozapine in February 2018. However, within 
one month of clozapine initiation, an amber result was recorded with a WBC of 3.3x109/l 
(neutrophils were normal at 2.4x109/l). To reduce the risk of clozapine discontinuation, we 
sought another haematology review to allow revised monitoring according to the US criteria 
which was agreed. The patient has been on this treatment plan for the last 6 months without 
any amber or red results (according to US criteria) with substantial improvement in her 
psychotic symptoms. 
 
  
Case 4: 
 
Ms D is a 49-year old Chinese female with treatment-resistant schizophrenia and multiple 
medical co-morbidities.  Her medical history includes Systemic Lupus Erythematosus (not 
active), and Autoimmune Haemolytic Anaemia (related to the SLE) – both stable on low dose 
steroids. She also had Chronic Kidney Disease stage 3 and had had deranged Liver Function 
Tests (LFT) for many years. Her MRI showed white matter hyperintensities and tonic-clonic 
seizures had been reported in June 2015. She had frequent low magnesium levels and was 
intermittently prescribed supplements.  She also had a history of type 2 diabetes, 
hypertension, hypercholesterolemia and recurrent Urinary Tract Infections (UTIs). Her very 
complicated medical picture together with a chronically low WBC had precluded a clozapine 
trial for over two decades until she was referred to our unit in December 2016. After extensive 
medical reviews by various specialists, clozapine was initiated in May 2017. Baseline 
investigations showed a WBC of 3.7x109/l and neutrophils of 2.26x109/l. Within 8 weeks of 
clozapine initiation, there was a remarkable improvement in her mental state and 
presentation. However during the same period, there were three amber results (using UK 
general population criteria) resulting in the requirement for twice weekly blood monitoring.  
We therefore undertook another haematology consultation to allow revised monitoring 
according to the US criteria, which was agreed with the clozapine registry. Despite monitoring 
according to the revised criteria, clozapine was discontinued in November 2017 and restarted 
after 10 days following two red results (WBC 2.05x109/l and neutrophils 1.2x109/l; WBC 
2.2x109/l and neutrophils 1.3x109/l). In this instance, clozapine treatment was interrupted 
 owing to the low total white cell count and not because of the neutrophil count. Eight months 
later, the patient has continued clozapine and maintains improvement in her mental state 
 
Discussion 
 
  
The role of clozapine in the treatment of patients with refractory psychotic illness is 
undisputed and it is not an exaggeration to say that its reintroduction in the 1990s radically 
changed many lives. However, it is also associated with a risk of some rare but potentially life-
threatening adverse reactions such as neutropenia, agranulocytosis, myocarditis and severe 
constipation. A significant proportion of patients are referred to the National Psychosis Unit 
(NPU), a tertiary-care clinical-academic psychiatric facility in South London, for possible 
clozapine rechallenge following the occurrence of some of these potentially serious adverse 
effects.  The unit works in close collaboration with various medical specialties and thus 
patients undergo thorough medical evaluations before such a rechallenge is undertaken.  
 
The cumulative incidence of agranulocytosis during clozapine treatment is estimated at 0.8% 
(Alvir et al., 1993) and that of neutropenia to be about 3% (Atkin et al., 1996).  To mitigate 
these risks, various guidelines have been adopted in different countries.  Regular blood 
monitoring is mandatory in most countries. However, not only is there wide variation in the 
frequency of blood monitoring across different countries, but the haematological threshold 
for clozapine treatment cessation also differs (Nielsen et al., 2016). This variation is not 
surprising as the evidence base for the details of haematological monitoring frequency and 
thresholds for cessation is weak and inevitably somewhat arbitrary.   
  
In Iceland, haematological monitoring during clozapine treatment is flexible and not 
rigorously enforced.  In a study of patients with schizophrenia comparing those on long-term 
clozapine treatment versus non-clozapine antipsychotics, mild neutropenia (1.5-1.9 x109/l) 
was significantly associated with clozapine compared with non-clozapine drugs (hazard ratio 
of 1.86).   Moderate to severe neutropenia (0-1.4 x109/l) on the other hand was more 
common in patients who had never been on clozapine despite having blood counts half as 
frequently as those on clozapine (Ingimarsson et al., 2016). The Iceland data suggest that 
many instances of neutropenia are probably unrelated to clozapine and very rarely progress 
to the more severe agranulocytosis.  The authors, Ingimarsson et al, call for a lower limit in 
line with the current US guidelines.  This is also consistent with reports that transient 
neutropenia occurs frequently during clozapine treatment (Hummer et al., 1994).  
 
Studies examining clozapine rechallenge in patients who developed neutropenia during 
treatment demonstrate that greater than 70% of challenges are successful (Meyer et al., 
2015; Prokopez et al., 2016). This suggests that many cases of neutropenia during clozapine 
may be chance findings, and that different mechanisms underlie the more benign 
neutropenia and the potentially lethal agranulocytosis. This further lends support to the 
results from the Icelandic study suggesting the risk of severe neutropenia or agranulocytosis 
with clozapine is probably not significantly different from other antipsychotic agents.  
 
It is well recognised that among the known barriers contributing to gross world-wide 
underutilisation of clozapine is the requirement for blood monitoring (Gee et al., 2014; 
Farooq et al., 2018). In a survey of international trends in clozapine use, Japan recorded the 
 lowest clozapine use which can be partially explained by the very strict regulations around 
clozapine initiation, including weekly haematological tests for 26 weeks and hospitalisation 
for the first 18 weeks (Bachmann et al., 2017).  
 
Two strategies commonly employed to manage clozapine-associated neutropenia are the use 
of lithium (Paton and Esop, 2005) and Granulocyte Colony-Stimulating Factor (G-CSF) (Lally et 
al., 2017; Myles et al., 2017).  These strategies are not without risks. The combined use 
clozapine and lithium may increase the risk of neurotoxic reactions (Bender et al., 2004) while 
there is a paucity of data on the use of G-CSF in preventing clozapine-associated 
haematological adverse effects (Lally et al., 2017). Long-term G-CSF adverse effects can 
include enlarged spleen, hepatomegaly, urinary abnormalities and very rarely, splenic rupture 
(Khan et al., 2013).   It could be argued that with the lowering of the threshold using the US 
criteria, such remedial strategies could become unnecessary in most instances. 
 
In two of the cases, (patients C and D), clozapine was discontinued not because of the 
neutrophil counts but because of the total white cell count (WCC). The need for clozapine 
cessation would have been unnecessary under the new US guidelines where the threshold for 
WCC has been removed.  An evaluation of the Clozapine Monitoring Programme for 1100 
patients registered for treatment at the South London and Maudsley NHS Foundation Trust 
from January to December 2017 showed 18 patients recorded 57 “red” results during the 
period. Of these, 16 results (from 6 patients) were due to a low total white cell count rather 
than low absolute neutrophil counts.  At follow up in 2018, three of these patients have 
ceased clozapine treatment while three have continued.   
 
 The impact and clinical safety of the new US guidelines have not been fully assessed.  An 
analysis of the potential impact of the changes using the Veterans Integrated Service Network 
7 (VISN 7) involving 246 clozapine recipients from 1999 to 2012 has been conducted (Sultan 
et al., 2017).  Under the old regulations, 5 patients (3.1%) of 160 qualified for clozapine 
cessation, whereas under the new guidelines, only 1 (0.6%) qualified for treatment 
discontinuation.     
 
 
 Conclusion: 
Clozapine is currently the most effective treatment available for patients with refractory 
schizophrenia but it is grossly underutilised. Mandatory haematological monitoring is a 
double-edged sword.  On one hand, it reduces clozapine-associated haematological toxicity; 
but on the other hand it precludes its use among patients who experience transient 
neutropenias that are probably unrelated to drug treatment. Adoption of BEN monitoring 
guidelines was a positive step in the right direction that has allowed may black patients to 
access clozapine treatment. It is timely to consider adopting the US guidelines.  This would 
obviate the need for frequent, repeated blood testing and unnecessary termination of 
treatment.  In addition,    it would further increase the potential number of patients that 
would benefit from this uniquely effective but underused treatment without compromising 
safety.   
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